Lantern Pharma LTRN
NASDAQ LTRN
$2.34 +0.05 (+2.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

Lantern Pharma (LTRN) Net Equity Issued and Repurchased (2022 - 2025)

Lantern Pharma's (LTRN) quarterly Net Equity Issued and Repurchased came in at $666208.0 in Q4 2025, up 2068.5% on a QoQ basis from $30722.0 in Q3 2025.

Lantern Pharma (LTRN) Net Equity Issued and Repurchased (2022 - 2025) Analysis & Trends

Lantern Pharma (LTRN) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $666208.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 49.20 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Lantern Pharma 26.05 Mn 26.05 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 666,208.00
Dec 31, 2025 666,208.00
Sep 30, 2025 30,722.00
Sep 30, 2025 30,722.00
Mar 31, 2022 299,788.00
Mar 31, 2022 299,788.00